- Home
- NXTC vs CHRO Comparison
NXTC vs CHRO Comparison
Compare NXTC & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- CHRO
- Stock Information
- Founded
- NXTC 2015
- CHRO 2002
- Country
- NXTC United States
- CHRO United States
- Employees
- NXTC N/A
- CHRO N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- CHRO
- Sector
- NXTC Health Care
- CHRO
- Exchange
- NXTC Nasdaq
- CHRO Nasdaq
- Market Cap
- NXTC 9.3M
- CHRO 8.1M
- IPO Year
- NXTC 2019
- CHRO 2024
- Fundamental
- Price
- NXTC $0.43
- CHRO $1.35
- Analyst Decision
- NXTC Strong Buy
- CHRO Strong Buy
- Analyst Count
- NXTC 2
- CHRO 1
- Target Price
- NXTC $3.50
- CHRO N/A
- AVG Volume (30 Days)
- NXTC 259.7K
- CHRO 2.0M
- Earning Date
- NXTC 05-05-2025
- CHRO 05-14-2025
- Dividend Yield
- NXTC N/A
- CHRO N/A
- EPS Growth
- NXTC N/A
- CHRO N/A
- EPS
- NXTC N/A
- CHRO N/A
- Revenue
- NXTC N/A
- CHRO N/A
- Revenue This Year
- NXTC N/A
- CHRO N/A
- Revenue Next Year
- NXTC N/A
- CHRO N/A
- P/E Ratio
- NXTC N/A
- CHRO N/A
- Revenue Growth
- NXTC N/A
- CHRO N/A
- 52 Week Low
- NXTC $0.22
- CHRO $0.45
- 52 Week High
- NXTC $1.82
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- NXTC 44.58
- CHRO 46.67
- Support Level
- NXTC $0.22
- CHRO $1.29
- Resistance Level
- NXTC $0.44
- CHRO $1.65
- Average True Range (ATR)
- NXTC 0.06
- CHRO 0.19
- MACD
- NXTC 0.02
- CHRO 0.02
- Stochastic Oscillator
- NXTC 86.11
- CHRO 13.79
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.